{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:20:04Z","timestamp":1793823604696,"version":"4.6.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:00Z","timestamp":1573862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"FDN","award":["143313"],"award-info":[{"award-number":["143313"]}]},{"name":"FDN","award":["154333"],"award-info":[{"award-number":["154333"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Hypertriglyceridaemia in patients with atherosclerotic cardiovascular disease (ASCVD) has been in focus following the REDUCE-IT trial showing benefit with icosapent ethyl. Among individuals with prevalent ASCVD, we sought to quantify the contemporary, real-world risk of ASCVD events associated with hypertriglyceridaemia, as well as estimate icosapent ethyl eligibility and compare trial participants with REDUCE-IT-like individuals in the population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We examined data from 2 424 865 adults with lipid panels in the Ontario population. Among those with prevalent ASCVD, we examined adjusted associations between triglyceride (TG) and ASCVD events (first occurrence of myocardial infarction, unstable angina, stroke or transient ischaemic attack, coronary revascularization, or cardiovascular death). The proportion of patients with ASCVD potentially eligible for icosapent ethyl was estimated as those with TG 135\u2013499\u2009mg\/dL (1.52\u20135.63\u2009mmol\/L) and low-density lipoprotein cholesterol (LDLc) 41\u2013100\u2009mg\/dL (1.06\u20132.59\u2009mmol\/L), similar to the lipid cut-offs in REDUCE-IT, and their demographics and event rates examined. Among 196 717 individuals with ASCVD, median age was 69\u2009years and 30% were female. A total of 24 097 composite ASCVD events occurred over a mean (standard deviation) 2.9 (0.5) years of follow-up. Increasing TG was associated with a graded, progressively higher hazard of ASCVD events. Twenty-five percent (49 886) of individuals with ASCVD had hypertriglyceridaemia and controlled LDLc; these patients were demographically similar to those in REDUCE-IT with comparable event rates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among patients with ASCVD, hypertriglyceridaemia is common, and is associated with higher ASCVD risk across a range of TG. It is possible that as many as one in four patients with ASCVD may be candidates for emerging therapies.<\/jats:p>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehz767","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T11:10:30Z","timestamp":1572088230000},"page":"86-94","source":"Crossref","is-referenced-by-count":102,"title":["Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5155-5071","authenticated-orcid":false,"given":"Patrick R","family":"Lawler","sequence":"first","affiliation":[{"name":"Peter Munk Cardiac Centre, University Health Network , 200 Elizabeth St, Toronto, Ontario, Canada"},{"name":"University of Toronto , 27 King's College Cir, Toronto, Ontario, Canada"},{"name":"Ted Rogers Centre for Heart Research, 661 University Avenue , 14th Floor, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gynter","family":"Kotrri","sequence":"additional","affiliation":[{"name":"University of Toronto , 27 King's College Cir, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Koh","sequence":"additional","affiliation":[{"name":"ICES , 2075 Bayview Avenue, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-2440","authenticated-orcid":false,"given":"Shaun G","family":"Goodman","sequence":"additional","affiliation":[{"name":"University of Toronto , 27 King's College Cir, Toronto, Ontario, Canada"},{"name":"St Michael's Hospital , 30 Bond St, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Farkouh","sequence":"additional","affiliation":[{"name":"Peter Munk Cardiac Centre, University Health Network , 200 Elizabeth St, Toronto, Ontario, Canada"},{"name":"University of Toronto , 27 King's College Cir, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S","family":"Lee","sequence":"additional","affiliation":[{"name":"Peter Munk Cardiac Centre, University Health Network , 200 Elizabeth St, Toronto, Ontario, Canada"},{"name":"University of Toronto , 27 King's College Cir, Toronto, Ontario, Canada"},{"name":"Ted Rogers Centre for Heart Research, 661 University Avenue , 14th Floor, Toronto, Ontario, Canada"},{"name":"ICES , 2075 Bayview Avenue, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Austin","sequence":"additional","affiliation":[{"name":"ICES , 2075 Bayview Avenue, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-9584","authenticated-orcid":false,"given":"Jacob A","family":"Udell","sequence":"additional","affiliation":[{"name":"Peter Munk Cardiac Centre, University Health Network , 200 Elizabeth St, Toronto, Ontario, Canada"},{"name":"University of Toronto , 27 King's College Cir, Toronto, Ontario, Canada"},{"name":"ICES , 2075 Bayview Avenue, Toronto, Ontario, Canada"},{"name":"Women's College Hospital, 76 Grenville St , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis T","family":"Ko","sequence":"additional","affiliation":[{"name":"Peter Munk Cardiac Centre, University Health Network , 200 Elizabeth St, Toronto, Ontario, Canada"},{"name":"University of Toronto , 27 King's College Cir, Toronto, Ontario, Canada"},{"name":"ICES , 2075 Bayview Avenue, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,16]]},"reference":[{"key":"2022102610552083300_ehz767-B1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/jamacardio.2016.4396","article-title":"Trends in total cholesterol, triglycerides, and low-density lipoprotein in US adults, 1999-2014","volume":"2","author":"Rosinger","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2022102610552083300_ehz767-B2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2012.13260","article-title":"Trends in lipids and lipoproteins in US adults, 1988-2010","volume":"308","author":"Carroll","year":"2012","journal-title":"JAMA"},{"key":"2022102610552083300_ehz767-B3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2022102610552083300_ehz767-B4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"2022102610552083300_ehz767-B5","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102610552083300_ehz767-B6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"2022102610552083300_ehz767-B7","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/ATVBAHA.116.308305","article-title":"Remnant cholesterol and triglyceride-rich lipoproteins in atherosclerosis progression and cardiovascular disease","volume":"36","author":"Varbo","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102610552083300_ehz767-B8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102610552083300_ehz767-B9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"2022102610552083300_ehz767-B10","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin Cardiol"},{"key":"2022102610552083300_ehz767-B11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCOUTCOMES.114.001416","article-title":"The Cardiovascular Health in Ambulatory Care Research Team (CANHEART): using big data to measure and improve cardiovascular health and healthcare services","volume":"8","author":"Tu","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022102610552083300_ehz767-B12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","article-title":"High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study","volume":"68","author":"Ko","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102610552083300_ehz767-B13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"2022102610552083300_ehz767-B14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am J Cardiol"},{"key":"2022102610552083300_ehz767-B15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022102610552083300_ehz767-B16","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102610552083300_ehz767-B17","doi-asserted-by":"crossref","first-page":"e008740.","DOI":"10.1161\/JAHA.118.008740","article-title":"High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk","volume":"7","author":"Toth","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022102610552083300_ehz767-B18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.13537","article-title":"Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol","volume":"21","author":"Nichols","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022102610552083300_ehz767-B19","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","article-title":"Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease","volume":"73","author":"Picard","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102610552083300_ehz767-B20","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102610552083300_ehz767-B21","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102610552083300_ehz767-B22","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102610552083300_ehz767-B23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005549","article-title":"Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol","volume":"6","author":"Lawler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022102610552083300_ehz767-B24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007402","article-title":"Residual risk of atherosclerotic cardiovascular events in relation to reductions in very-low-density lipoproteins","volume":"6","author":"Lawler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022102610552083300_ehz767-B25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","article-title":"2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult\u20142009 recommendations","volume":"25","author":"Genest","year":"2009","journal-title":"Can J Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/1\/86\/46642827\/eurheartj_41_1_86.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/1\/86\/46642827\/eurheartj_41_1_86.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T10:59:35Z","timestamp":1666781975000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/1\/86\/5625151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,11,16]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz767","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1,1]]},"published":{"date-parts":[[2019,11,16]]}}}